Intra-Cellular Therapies Inc
NASDAQ:ITCI
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
81.78
131.92
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one
ITCI
stock under the Base Case scenario is
93.97
USD.
Compared to the current market price of 131.87 USD,
Intra-Cellular Therapies Inc
is
Overvalued by 29%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.
Let our AI break down the key assumptions behind the intrinsic value calculation for Intra-Cellular Therapies Inc.
| US |
|
Eli Lilly and Co
NYSE:LLY
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Heightened reliance on CAPLYTA leaves the firm vulnerable if commercial uptake underperforms — with almost all revenues riding on a single product, any shift in physician prescribing habits or unexpected regulatory snags could sharply impact top-line results.
Competition from well-established antipsychotics and newer treatments may constrain CAPLYTA’s market share — entrenched pharmaceutical players with broader sales networks and deeper resources could aggressively defend their schizophrenia and bipolar depression therapies, limiting Intra-Cellular’s room to grow.
Expanding into other indications and advancing early-stage pipelines strains capital resources — the firm’s ongoing R&D efforts involve significant up-front costs, and any pipeline disappointment could force hefty additional fundraising or dilute existing shareholders.
CAPLYTA’s strong efficacy-benign side effect profile in schizophrenia and bipolar depression positions it as a potential best-in-class therapy — positive feedback from both patients and clinicians could accelerate market adoption and boost revenue growth.
Expansion into adjunctive uses and new indications provides a long runway — clinical trials exploring CAPLYTA’s potential in major depressive disorder and other psychiatric conditions could diversify revenue sources and reduce reliance on a single label.
Early-stage PDE1 inhibitor portfolio may unlock substantial new market opportunities beyond psychiatry — if pivotal trials confirm efficacy in areas such as heart failure or other central nervous system disorders, Intra-Cellular could secure lucrative avenues of growth.
Revenue & Expenses Breakdown
Intra-Cellular Therapies Inc
Balance Sheet Decomposition
Intra-Cellular Therapies Inc
| Current Assets | 1.3B |
| Cash & Short-Term Investments | 1B |
| Receivables | 166.5m |
| Other Current Assets | 139.8m |
| Non-Current Assets | 59.5m |
| PP&E | 14.9m |
| Other Non-Current Assets | 44.7m |
| Current Liabilities | 205.7m |
| Accounts Payable | 26.1m |
| Accrued Liabilities | 179.6m |
| Non-Current Liabilities | 12.7m |
| Other Non-Current Liabilities | 12.7m |
Free Cash Flow Analysis
Intra-Cellular Therapies Inc
| USD | |
| Free Cash Flow | USD |
Earnings Waterfall
Intra-Cellular Therapies Inc
|
Revenue
|
680.9m
USD
|
|
Cost of Revenue
|
-57m
USD
|
|
Gross Profit
|
623.9m
USD
|
|
Operating Expenses
|
-740.6m
USD
|
|
Operating Income
|
-116.7m
USD
|
|
Other Expenses
|
42m
USD
|
|
Net Income
|
-74.7m
USD
|
ITCI Profitability Score
Profitability Due Diligence
Intra-Cellular Therapies Inc's profitability score is 31/100. The higher the profitability score, the more profitable the company is.
Score
Intra-Cellular Therapies Inc's profitability score is 31/100. The higher the profitability score, the more profitable the company is.
ITCI Solvency Score
Solvency Due Diligence
Intra-Cellular Therapies Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
Intra-Cellular Therapies Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ITCI Price Targets Summary
Intra-Cellular Therapies Inc
Dividends
Current shareholder yield for
ITCI is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
ITCI
stock under the Base Case scenario is
93.97
USD.
Compared to the current market price of 131.87 USD,
Intra-Cellular Therapies Inc
is
Overvalued by 29%.